SSR 101010

Drug Profile

SSR 101010

Alternative Names: SSR101010

Latest Information Update: 17 Mar 2009

Price : $50

At a glance

  • Originator sanofi-aventis
  • Class Antidepressants; Anxiolytics
  • Mechanism of Action Fatty acid amide hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Anxiety disorders; Major depressive disorder

Most Recent Events

  • 11 Feb 2009 Discontinued - Phase-I for Depression in USA (unspecified route)
  • 11 Feb 2009 Discontinued - Phase-I for Anxiety disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top